-Advertisement-
-Advertisement-
Lupus Nephritis
Active disease, end-stage renal disease drive costs in lupus nephritis
Due to the high treatment burden and cost of patients with active disease and end-stage renal disease (ESRD) in Lupus nephritis (LN), achieving and maintaining low disease activity may help reduce medication use and overall healthcare costs, according to a study. In this retrospective analysis, total healthcare payer costs for...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2025 Med Journal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved